The estimated Net Worth of Joseph M Miller is at least $2.96 Million dollars as of 6 March 2024. Mr. Miller owns over 34,811 units of Cerecor Inc stock worth over $1,453,069 and over the last 6 years he sold CERC stock worth over $332,678. In addition, he makes $1,170,600 as Director at Cerecor Inc.
Joseph has made over 6 trades of the Cerecor Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 34,811 units of CERC stock worth $194,942 on 6 March 2024.
The largest trade he's ever made was selling 34,811 units of Cerecor Inc stock on 6 March 2024 worth over $194,942. On average, Joseph trades about 3,173 units every 102 days since 2018. As of 6 March 2024 he still owns at least 495,928 units of Cerecor Inc stock.
You can see the complete history of Mr. Miller stock trades at the bottom of the page.
Joseph M. Miller CPA serves as Director of the Company. Mr. Miller brings over 20 years of experience and a wealth of financial knowledge as a senior executive with extensive hands-on experience in managing financial operations and supporting enterprise growth across the health sciences, biotech and pharmaceutical sectors. Mr. Miller currently serves as the Chief Financial Officer of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). Prior to that, he served as the Company’s Chief Financial Officer and Principal Financial Officer from July 2018 until April 2020. Mr. Miller served as the Company’s Principal Executive Officer from April 2019 to February 2020. Prior to joining Cerecor, Mr. Miller was the Vice President of Finance at Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) from 2015 through April 2018 where he was responsible for building out the finance organization to effectively support the company's rapid growth, ultimately resulting in the $1.2 billion merger with Mallinckrodt in early 2018. From 2006 through 2015, Mr. Miller was the Senior Director of Accounting at QIAGEN and from 2002 to 2006 he served as Vice President of Finance and Chief Financial Officer of Eppendorf-5Prime. Mr. Miller began his career at KPMG LLP. Mr. Miller holds a B.S. degree in accounting from Villanova University and is a Certified Public Accountant. Our Board believes that Mr. Miller’s experience in managing the financial operations and supporting enterprise growth across the health sciences, biotech and pharmaceutical sectors makes him a valuable member of our Board.
As the Director of Cerecor Inc, the total compensation of Joseph Miller at Cerecor Inc is $1,170,600. There are no executives at Cerecor Inc getting paid more.
Joseph Miller is 46, he's been the Director of Cerecor Inc since 2020. There are 7 older and 2 younger executives at Cerecor Inc. The oldest executive at Cerecor Inc is Sol Barer, 72, who is the Chairman of the Board.
Joseph's mailing address filed with the SEC is #140, 14315 -118 AVENUE, , EDMONTON, A0, T5L 4S6.
Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell und Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.
Cerecor Inc executives and other stock owners filed with the SEC include: